This Company engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA . CRSP and Vertex creates new possibilities in medicine to cure diseases and improve people's lives. We work with leading researchers,...
Engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. Shareholders may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term...
A company that designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. anticipates two regulatory approvals for berotralstat in 2020, Even more impressive, that BCRX will likely get a significant near-term boost from the success of...
The company's approach delivers better clinical and financial outcomes while creating a different and better experience for people with chronic conditions. With that, the stock is performing so well that it appears to outdone other sector peers. This would seems to me that this stock may outperform the market over the next one to three months and continue bullish...
4H Chart Explanation: - Price broke the ATH Zone (Resistance). - Price is currently on a lateralization. - If price breaks it, potential to move up towards the Fibo Zones. Weekly Vision: Daily Vision: Updates coming soon!
The NASDAQ Composite it’s showing sign of weakness now, but despite of the two last red candles, it’s still a bullish trend . The price is trading inside an ascending channel, and it found support at the purple trendline again. The price is trading above the 21 ema and above the previous top zone, which is evidenced by the pink line. It lost today the 8950 (thin...
$MARK is pulling back after hit the pivot resistance. It is most likely pull back till 20SMA. There is negative divergence too. If you find my charts useful, please leave me a just "Like" thank you
Stock jumped as first-quarter earnings and revenue beat expectations on growth in education, healthcare and retail sectors amid the coronavirus emergency. Twilio's software makes it easier for cloud-based applications to communicate.
MDGS a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced that following the signing of a collaboration agreement with L-1 Systems Ltd. This thing has soared after the announcement about getting the first, commercial order for COVID19 testing kits! From 2.28 to 3.46 after a single day is...
ServiceNow jumped %12 last week with the help of earning results and forming a cup. To be confirmed needs to get above $362.95
engages in the development of transformative medicines based on messenger ribonucleic acid. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. GOOD OF START of the company of may...
NASDAQ pulled back way more than expected, and took out our SLs. But we now have the otential to make that money back and some!
If we completely ignore the news, the graph of QQQ seems to be recovering quite nicely. For a technical trader it's extremely optimistic. Then, if you look at any sort of news, this trading at Jan 2020 levels seems absolutely insane. Both sides have good cases, but I am going to choose to ignore each of them. The indexes are beyond unpredictable right now (see GDP...
$SD a company engaged in hydrocarbon exploration in the US hold true to it's name, a strong and successful market to be on interest of. While the slide is underneath, being on bearish trend during this pandemic doesn't seems a big deal. Market is still working on it's principal focus on generating & developing high potential oil and gas assets in the U.S. given...
As Eagle Pharma Win Patent Decision for Bendeka, Court issued a favorable patent decision for Bendeka bendamustine hydrochloride injection, or bendamustine HCl , a liquid, low-volume and short-time 10-minute infusion formulation of bendamustine hydrochloride. So with that $EGRX shares rose 23% to $63.25 in premarket trading. With ongoing evaluation of the efficacy...
AXSM clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system, it is accelerating the completion of the ADVANCE-1 Phase 2/3 trial of AXS-05 in patients with Alzheimer’s disease agitation to ensure the safety of this vulnerable patient population during the COVID-19 pandemic. i expect that this end of the...